Notification report

Full notification file

General information

Notification Number

Member State to which the notification was sent

Date of acknowledgement from the Member State Competent Authority

Title of the Project
A Randomized, Double-Blind, Placebo-controlled, Parallel, Exploratory Phase 2a Study to Evaluate Safety and Biological Effect of ILP100 in Patients with Diabetic Foot Ulcers

Proposed period of release:
01/04/2021 to 31/12/2022

Name of the Institute(s) or Company(ies)
Ilya Pharma, AB, ;

3. Is the same GMO release planned elsewhere in the Community?

Has the same GMO been notified elsewhere by the same notifier?

If yes, notification number(s):

GMO characterization

GMO is a:

Identity of the GMO:
Order: Lactobacillales Genus: Limosilactobacillus Species: Limosilactobacillus reuteri

Information relating to the recipient or parental organisms from wich the GMO is derived
Common NameGenusSpeciesSubspeciesStrainPathovar
L. reuteri R2LCLimosilactobacillusLimosilactobacillus reuteriN/AL. reuteri R2LCN/A

European Commission administrative information

Consent given by the Member State Competent Authority:
Not known